1.	Phase II Study of MART-1/gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail in Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: LAC-USC-10M-03-1, 6262, NCI-6262, LAC-USC-033307, NCT00334776
2.	Phase II Randomized Study of Ipilimumab With Versus Without gp100 Peptides Emulsified in Montanide ISA-51 in Patients With Previously Treated, HLA-A*0201 Positive Stage IV Melanoma Phase: Phase II Type: Treatment Status: Closed Age: 16 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: NCI-06-C-0159, NCI-P6951, MDX-NCI-06-C-0159, NCT00357461
3.	Pilot Study of a Peptide Vaccine Comprising MART-1:27-35 Peptide, gp100:209-217 (210M) Peptide, and Tyrosinase Peptide With Sargramostim (GM-CSF) and CpG 7909 Emulsified in Incomplete Freund's Adjuvant in Patients With Unresectable Recurrent Stage III or IV Melanoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: PCI-04173, 04-173, PCI-IRB-0607048, 7357, NCT00471471